MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $100,019 | $99,915 |
| Restricted cash | 5,000 | — |
| Marketable securities | 826,232 | 534,216 |
| Trade receivables, net | 53,822 | — |
| Inventory | 34,068 | — |
| Prepaid expenses and other current assets | 13,786 | 3,150 |
| Total current assets | 1,032,927 | 637,281 |
| Property and equipment, net | 2,190 | 1,553 |
| Intangible assets, net | 4,729 | — |
| Right-of-use asset | 2,401 | 1,713 |
| Total assets | $1,042,247 | $640,547 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $43,599 | $28,041 |
| Accrued liabilities | 124,695 | 89,980 |
| Lease liability | 983 | 527 |
| Total current liabilities | 169,277 | 118,548 |
| Long term liabilities: | ||
| Loan payable, net of discount | 117,569 | 115,480 |
| Lease liability | 1,018 | 1,186 |
| Total long term liabilities | 118,587 | 116,666 |
| Total liabilities | 287,864 | 235,214 |
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at December 31, 2024 and December 31, 2023; 2,369,797 and 2,369,797 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, par value $0.0001 per share authorized: 200,000,000 at December 31, 2024 and December 31, 2023; 22,004,679 and 19,875,427 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 2 | 2 |
| Additional paid-in-capital | 2,556,095 | 1,741,153 |
| Accumulated other comprehensive income | 468 | 468 |
| Accumulated deficit | (1,802,182) | (1,336,290) |
| Total stockholders’ equity | 754,383 | 405,333 |
| Total liabilities and stockholders’ equity | $1,042,247 | $640,547 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.